vs
Citi Trends Inc（CTRN）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是Citi Trends Inc的1.0倍（$197.9M vs $197.1M），REPLIGEN CORP净利率更高（6.7% vs -3.5%，领先10.2%），REPLIGEN CORP同比增速更快（13.6% vs 10.1%），REPLIGEN CORP自由现金流更多（$17.6M vs $767.0K），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs -4.3%）
Citi Trends Inc是一家美国服装零售连锁品牌，主营折扣服饰商品，目标客群以非裔美国人为主，凭借高性价比的产品策略在美国本土折扣零售市场占据一席之地。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
CTRN vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.0倍
$197.1M
营收增速更快
RGEN
高出3.6%
10.1%
净利率更高
RGEN
高出10.2%
-3.5%
自由现金流更多
RGEN
多$16.8M
$767.0K
两年增速更快
RGEN
近两年复合增速
-4.3%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $197.1M | $197.9M |
| 净利润 | $-6.9M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | -3.7% | 9.0% |
| 净利率 | -3.5% | 6.7% |
| 营收同比 | 10.1% | 13.6% |
| 净利润同比 | 3.6% | 143.9% |
| 每股收益（稀释后） | $-0.86 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTRNRGEN
| Q4 25 | $197.1M | $197.9M | ||
| Q3 25 | $190.8M | $188.8M | ||
| Q2 25 | $201.7M | $182.4M | ||
| Q1 25 | $211.2M | $169.2M | ||
| Q4 24 | $179.1M | $174.1M | ||
| Q3 24 | $176.6M | $154.9M | ||
| Q2 24 | $186.3M | $154.1M | ||
| Q1 24 | $215.2M | $151.3M |
净利润CTRNRGEN
| Q4 25 | $-6.9M | $13.3M | ||
| Q3 25 | $3.8M | $14.9M | ||
| Q2 25 | $871.0K | $14.9M | ||
| Q1 25 | $-14.2M | $5.8M | ||
| Q4 24 | $-7.2M | $-30.3M | ||
| Q3 24 | $-18.4M | $-654.0K | ||
| Q2 24 | $-3.4M | $3.3M | ||
| Q1 24 | $3.6M | $2.1M |
毛利率CTRNRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率CTRNRGEN
| Q4 25 | -3.7% | 9.0% | ||
| Q3 25 | 1.8% | 8.9% | ||
| Q2 25 | 0.2% | 7.6% | ||
| Q1 25 | 0.6% | 3.9% | ||
| Q4 24 | -4.9% | -17.7% | ||
| Q3 24 | -14.1% | -5.1% | ||
| Q2 24 | -3.7% | 1.0% | ||
| Q1 24 | 1.8% | 1.3% |
净利率CTRNRGEN
| Q4 25 | -3.5% | 6.7% | ||
| Q3 25 | 2.0% | 7.9% | ||
| Q2 25 | 0.4% | 8.2% | ||
| Q1 25 | -6.7% | 3.4% | ||
| Q4 24 | -4.0% | -17.4% | ||
| Q3 24 | -10.4% | -0.4% | ||
| Q2 24 | -1.8% | 2.2% | ||
| Q1 24 | 1.7% | 1.4% |
每股收益（稀释后）CTRNRGEN
| Q4 25 | $-0.86 | $0.24 | ||
| Q3 25 | $0.46 | $0.26 | ||
| Q2 25 | $0.11 | $0.26 | ||
| Q1 25 | $-1.70 | $0.10 | ||
| Q4 24 | $-0.86 | $-0.55 | ||
| Q3 24 | $-2.21 | $-0.01 | ||
| Q2 24 | $-0.42 | $0.06 | ||
| Q1 24 | $0.43 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $107.8M | $2.1B |
| 总资产 | $464.3M | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资CTRNRGEN
| Q4 25 | — | $767.6M | ||
| Q3 25 | — | $748.7M | ||
| Q2 25 | — | $708.9M | ||
| Q1 25 | — | $697.2M | ||
| Q4 24 | — | $757.4M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | — | $809.1M | ||
| Q1 24 | — | $780.6M |
总债务CTRNRGEN
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CTRNRGEN
| Q4 25 | $107.8M | $2.1B | ||
| Q3 25 | $113.2M | $2.1B | ||
| Q2 25 | $108.6M | $2.1B | ||
| Q1 25 | $113.2M | $2.0B | ||
| Q4 24 | $130.3M | $2.0B | ||
| Q3 24 | $136.6M | $2.0B | ||
| Q2 24 | $154.8M | $2.0B | ||
| Q1 24 | $157.7M | $2.0B |
总资产CTRNRGEN
| Q4 25 | $464.3M | $2.9B | ||
| Q3 25 | $457.4M | $2.9B | ||
| Q2 25 | $437.4M | $2.9B | ||
| Q1 25 | $462.8M | $2.9B | ||
| Q4 24 | $467.1M | $2.8B | ||
| Q3 24 | $506.7M | $2.8B | ||
| Q2 24 | $484.1M | $2.9B | ||
| Q1 24 | $518.7M | $2.8B |
负债/权益比CTRNRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.6M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $767.0K | $17.6M |
| 自由现金流率自由现金流/营收 | 0.4% | 8.9% |
| 资本支出强度资本支出/营收 | 4.0% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | $11.9M | $93.9M |
8季度趋势，按日历期对齐
经营现金流CTRNRGEN
| Q4 25 | $8.6M | $25.7M | ||
| Q3 25 | $3.9M | $48.1M | ||
| Q2 25 | $-11.0M | $28.6M | ||
| Q1 25 | $28.5M | $15.0M | ||
| Q4 24 | $-18.4M | $39.2M | ||
| Q3 24 | $5.6M | $49.3M | ||
| Q2 24 | $-19.6M | $42.2M | ||
| Q1 24 | $23.3M | $44.7M |
自由现金流CTRNRGEN
| Q4 25 | $767.0K | $17.6M | ||
| Q3 25 | $-1.7M | $43.4M | ||
| Q2 25 | $-13.1M | $21.5M | ||
| Q1 25 | $26.0M | $11.4M | ||
| Q4 24 | $-20.4M | $33.6M | ||
| Q3 24 | $1.7M | $42.3M | ||
| Q2 24 | $-21.2M | $37.4M | ||
| Q1 24 | $20.0M | $36.4M |
自由现金流率CTRNRGEN
| Q4 25 | 0.4% | 8.9% | ||
| Q3 25 | -0.9% | 23.0% | ||
| Q2 25 | -6.5% | 11.8% | ||
| Q1 25 | 12.3% | 6.8% | ||
| Q4 24 | -11.4% | 19.3% | ||
| Q3 24 | 0.9% | 27.3% | ||
| Q2 24 | -11.4% | 24.3% | ||
| Q1 24 | 9.3% | 24.0% |
资本支出强度CTRNRGEN
| Q4 25 | 4.0% | 4.1% | ||
| Q3 25 | 2.9% | 2.5% | ||
| Q2 25 | 1.0% | 3.9% | ||
| Q1 25 | 1.2% | 2.1% | ||
| Q4 24 | 1.1% | 3.2% | ||
| Q3 24 | 2.2% | 4.5% | ||
| Q2 24 | 0.9% | 3.1% | ||
| Q1 24 | 1.5% | 5.5% |
现金转化率CTRNRGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | 1.01× | 3.23× | ||
| Q2 25 | -12.59× | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | 6.56× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
